Stem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market

Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Stem Cells in Regenerative Medicine: Benchmarking Analysis of BigCompanies Entering the MarketPublished on December 2011 Report SummaryExecutive SummaryThis report reviews and analyzes the big healthcare companies that are entering the field of stem cells in regenerative medicine andstem cells in drug discovery. The research report uses the case study format to benchmark the biggest pharmaceutical or life sciencetools companies that have entered the stem cell market.The Big Pharma companies are working with the stem cells in regenerative medicine to develop new cell therapies to will help growtheir future pipelines. The report reviews what new stem cell based therapies might become available. The drug makers have alsobecome interested in the potential opportunity to improve their chances for making safer future drugs by using pluripotent stem cells,such as human embryonic stem cells (hESCs) or induced pluripotent stemcells (iPSCs), as well as various kinds of adult stem cells tomake customized, disease focused cells used in cell screening campaigns in drug discovery toxicity or efficacy testing. Thecustomized human stem cell-derived cells would eliminate the need to sacrifice millions of lab animals that are currently used in drugsafety testing.The study uncovers interesting information about major life science research tools companies working in the stem cell field that supplykey products and services to pharma and academic life science researchers working in stem cell R&D. The report reviews thesources of government and private stem cell research investment. Research and development work in all forms of stem cells isunderway at universities, government labs, institutes, cancer centers, hospitals and at drug makers or cell therapeutics companies.This research report is designed for people that include marketers, business development, top executives, investors, VCs,consultants, R&D managers, entrepreneurs and etc. More than 16 detailed tables or figures provide key data about items such asclinical trials, M&As, disease demographics and the like. This report includes seven benchmarking case studies and thirty-eightcompany profiles that provide the reader with a snapshot of the companies focus or activities. The provided Internet links helpreaders access companies own websites for further review.Benchmarking Analysis Case of Big Companies Entering the MarketCommon Research Items:-Stem Cell Program/Group Overview-Strategic Focus for Stem Cell Innovations-Major Corp. Deals, Investment, M&A, etc.-Stem Cell Related Product Pipeline-Stem Cell Related R&DR&D OrganizationResearch Network including R&D CentersBudgetNumber of ResearchersStem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market (From Slideshare) Page 1/9

Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Target R&D Domain and Noteworthy AreaDeveloping TechnologiesR&D to Commercialization Roadmap-Analysts Comment Table of ContentTable of Contents1. Overview: Commercializing Stem Cell Business Opportunities in Regenerative Medicine1.1 Stem Cells in the Regenerative Medicine Market Space1.2 Definitions1.2.1 Regenerative Medicine1.2.2 Stem cells1.2.3 Kinds of Companies1.2.4 Origins of Stem Cell Research1.3 Estimated Business Opportunity1.3.1 The Stem Cells in Drug Discovery Testing1.3.2 Stem Cells in Regenerative Medicine Therapy2. Worldwide Stem Cell Legal Update2.1 Overview2.2 North America2.2.1 Canada2.2.2 USA2.2.2.1 2001-2009 President Bushs Stem Cell Rules Were in Effect2.2.2.2 Apr.-2009, President Obama Reversed The President Bush Restrictions On Embryonic Stem Cell Research2.2.2.3 Sept.-2010, Sherley v. Sibellius Lawsuit Court Decision and The Dickey-Wicker Amendment2.2.2.4 Apr.-2011, Obama Administration Won Its Appeal To The Sherley v. Sibellius Decision2.2.2.5 NIH Approved More hESC Lines2.2.2.6 The FDA Approved A Cell Therapy Product2.2.2.7 FDA Approved New hES Cell Therapy Clinical Trials2.2.3 US States2.2.3.1 California2.3 Europe2.3.1 United Kingdom2.3.2 France2.3.3 Germany2.3.4 Belgium2.3.5 ItalyStem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market (From Slideshare) Page 2/9

Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!2.3.6 Sweden2.3.7 Spain2.4 Middle East2.4.1 Israel2.4.2 Saudi Arabia2.4.3 Iran2.5 Asia2.5.1 Japan2.5.2 South Korea2.5.3 India2.5.4 China2.6 Oceania2.6.1 Australia2.6.2 New Zealand2.7 Latin America2.7.1 Brazil2.7.2 Mexico2.8 Africa2.8.1 South Africa3. Competitive Benchmarking Analysis Cases of Big Companies Working in Stem Cells3.1 Pfizer, Inc.3.1.1 Stem Cell Program/Group Overview3.1.2 Strategic Focus for Stem Cell Innovations3.1.3 Major Corp. Deals, Investment, M&A, etc.3.1.4 Stem Cell Related Product Pipeline3.1.5 Stem Cell Related R&D3.1.5.1 R&D Organization3.1.5.2 Research Network including R&D Centers3.1.5.3 Budget3.1.5.4 Number of Researchers3.1.5.5 Target R&D Domain and Noteworthy Area3.1.5.6 Developing Technologies3.1.5.7 R&D to Commercialization Roadmap3.1.6 Analysts Comment3.2 Novartis AG3.2.1 Stem Cell Program/Group Overview3.2.2 Strategic Focus for Stem Cell Innovations3.2.3 Major Corp. Deals, Investment, M&A, etc.3.2.4 Stem Cell Related Product Pipeline3.2.5 Stem Cell Related R&D3.2.5.1 R&D Organization3.2.5.2 Research Network including R&D Centers3.2.5.3 Budget3.2.5.4 Number of Researchers3.2.5.5 Target R&D Domain and Noteworthy AreaStem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market (From Slideshare) Page 3/9

Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!3.2.5.6 Developing Technologies3.2.5.7 R&D to Commercialization Roadmap3.2.6 Analysts Comment3.3 Sanofi SA3.3.1 Stem Cell Program/Group Overview3.3.2 Strategic Focus for Stem Cell Innovations3.3.3 Major Corp. Deals, Investment, M&A, etc.3.3.4 Stem Cell Related Product Pipeline3.3.5 Stem Cell Related R&D3.3.5.1 R&D Organization3.3.5.2 Research Network including R&D Centers3.3.5.3 Budget3.3.5.4 Number of Researchers3.3.5.5 Target R&D Domain and Noteworthy Area3.3.5.6 Developing Technologies3.3.5.7 R&D to Commercialization Roadmap3.3.6 Analysts Comment3.4 GlaxoSmithKline3.4.1 Stem Cell Program/Group Overview3.4.2 Strategic Focus for Stem Cell Innovations3.4.3 Major Corp. Deals, Investment, M&A, etc.3.4.4 Stem Cell Related Product Pipeline3.4.5 Stem Cell Related R&D3.4.5.1 R&D Organization3.4.5.2 Research Network including R&D Centers3.4.5.3 Budget3.4.5.4 Number of Researchers3.4.5.5 Target R&D Domain and Noteworthy Area3.4.5.6 Developing Technologies3.4.5.7 R&D to Commercialization Roadmap3.4.6 Analysts Comment3.5 AstraZeneca3.5.1 Stem Cell Program/Group Overview3.5.2 Strategic Focus for Stem Cell Innovations3.5.3 Major Corp. Deals, Investment, M&A, etc.3.5.4 Stem Cell Related Product Pipeline3.5.5 Stem Cell Related R&D3.5.5.1 R&D Organization3.5.5.2 Research Network including R&D Centers3.5.5.3 Budget3.5.5.4 Number of Researchers3.5.5.5 Target R&D Domain and Noteworthy Area3.5.5.6 Developing Technologies3.5.5.7 R&D to Commercialization Roadmap3.5.6 Analysts Comment3.6 Roche3.6.1 Stem Cell Program/Group Overview3.6.2 Strategic Focus for Stem Cell InnovationsStem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market (From Slideshare) Page 4/9

Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!3.6.3 Major Corp. Deals, Investment, M&A, etc.3.6.4 Stem Cell Related Product Pipeline3.6.5 Stem Cell Related R&D3.6.5.1R&D Organization3.6.5.2 Research Network including R&D Centers3.6.5.3 Budget3.6.5.4 Number of Researchers3.6.5.5 Target R&D Domain and Noteworthy Area3.6.5.6 Developing Technologies3.6.5.7 R&D to Commercialization Roadmap3.6.6 Analysts Comment (Jay to write)3.7 GE Healthcare Life Sciences3.7.1 Stem Cell Program/Group Overview3.7.2 Strategic Focus for Stem Cell Innovations3.7.3 Major Corp. Deals, Investment, M&A, etc.3.7.4 Stem Cell Related Product Pipeline3.7.5 Stem Cell Related R&D3.7.5.1 R&D Organization3.7.5.2 Research Network including R&D Centers3.7.5.3 Budget3.7.5.4 Number of Researchers3.7.5.5 Target R&D Domain and Noteworthy Area3.7.5.6 Developing Technologies3.7.5.7 R&D to Commercialization Roadmap3.7.6 Analysts Comment4. Activities of Companies in Stem Cell R&D4.1 Big Pharma Companies4.1.1 Astellas Pharma, Inc.4.1.2 Johnson and Johnson4.1.3 Shire plc4.1.4 Takeda Pharmaceutical Co. Ltd.4.1.5 Teva Pharmaceuticals Ltd.4.2Cell Therapy Developers4.2.1 Advanced Cell Technology4.2.2 Athersys, Inc.4.2.3 BioTime, Inc.4.2.4 Capricor Inc.4.2.5 Dendreon Corporation4.2.6 Fate Therapeutics, Inc.4.2.7 Geron Corporation4.2.8 Mesoblast Ltd4.2.9 Pluristem Therapeutics4.3 Research Tools & Technology Companies4.3.1 America Stem Cell Inc.4.3.2 Beckman Coulter, Inc. (Danaher)Stem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market (From Slideshare) Page 5/9

Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!4.3.3 Becton, Dickinson & Co.4.3.4 Merck KGaA/ EMD Millipore Corporation4.3.5 GIRUS Life Sciences, Inc.4.3.6 Life Techologies, Inc.4.3.7 Luminex Corporation4.3.8 PerkinElmer, Inc.4.3.9 SABioscience Corporation (Qiagen)4.3.10 Sigma-Aldrich Corporation4.3.11 TAP Biosystems4.3.12 Tecan Group Ltd.4.3.13 Thermo Fisher Scientific Inc.4.4 Stem Cell Line Manufacturers4.4.1 AuxoCell Laboratories, Inc.4.4.2 Axiogenesis AG4.4.3 Axxam SpA4.4.4 California Stem Cell, Inc.4.4.5 Cellular Dynamics International4.4.6 iPierian, Inc.4.4.7 Lonza AG4.5 Medical Device Companies4.5.1 Baxter International Inc.4.5.2 MaxCyte, Inc.4.5.3 Cytori Therapeutics, Inc.4.5.4 Medtronic, Inc.5. Commercial Opportunities Identified for Stem Cells in Regenerative Medicine5.1 Key Findings5.1.1 Big Companies Entered the Stem Cell Field with Need for Partners.5.1.2 US Federal Funding Continues for Embryonic Stem Cell Research5.1.3 European High Court Banned hESC Methods Patents5.1.4 Venture Capital Averse to Biotech and Stem Cell Companies5.1.5 Congress Automatic Deficit Plan to Stem Cell Research Funding5.2 Analysts Benchmarking Summary5.3 Likely Opportunities and Challenges 5.3.1 Political Stem Cell Controversies Expanded Public Interest and Awareness of theMedical Benefits of Stem Cell Research5.3.2 Challenges to Stem Cell Research5.3.3 Global Investment Spending for Stem Cell Research to 20165.4 Commercial Implications5.4.1 Opportunities for American and European Companies5.4.1.1 Stem Cell Research Tools5.4.1.2 Explore Other WW Regions for Cost Savings or New Customers5.4.1.3 Asia Offers Business Opportunities5.4.2 New Opportunities for Japanese and Asian CompaniesStem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market (From Slideshare) Page 6/9

Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!6. Appendix6.1 Glossary of Terms: Stem Cells in Regenerative Medicine6.2 Industry and Company Contacts6.3 Big Company Benchmarking Summary DataList of TablesTable 1. Highlights of Stem Cell Research MilestonesTable 2. Pfizers Regenerative Medicine PipelineTable 3. Novartis Stem Cell Related Product PipelineTable 4. Sanofis Regenerative Medicine PipelineTable 5. GSKs Regenerative Medicine Related PipelineTable 6. AstraZenecas Regenerative Medicine PipelineTable 7. Roches Stem Cell Related Product PipelineTable 8. GEHC Stem Cell Related Product PipelineTable 9. Global Investment Spending for Stem Cell Research to 2016Table 10. Glossary of Stem Cell TermsTable 11. Large International Life Science R&D CentersTable 12. Selected Company ContactsTable 13. Big Companies by Summary of Stem Cell R&D Data EstimatesList of IllustrationsFigure 1. Stem Cells in the Regenerative Medicine Market SpaceFigure 2. PubMed Articles about Stem Cells Are GrowingFigure 3. The Drug Discovery ProcessFigure 4. Retina From a Patient Affected with AMDStem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market (From Slideshare) Page 7/9

Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Stem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market Product Formats Please select the product formats and the quantity you require. Hard Copy--USD 1 495.00 Quantity: _____ Department License--USD 2 295.00 Quantity: _____ Corporate License--USD 3 995.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Stem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market (From Slideshare) Page 8/9

Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature: Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Stem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market (From Slideshare) Page 9/9

Stem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market

by ReportLinker.com

Accessibility

Upload Details

Usage Rights

Statistics

Stem Cells in Regenerative Medicine: Benchmarking Analysis of Big Companies Entering the Market Document Transcript